Intranasal fluticasone propionate reduces ICAM‐1 on nasal epithelial cells both during early and late phase after allergen challenge

Ciprandi, Giorgio; Ricca, V.; Passalacqua, Giovanni; Fasolo, Adriano; Canonica, Giorgio Walter

doi:10.1046/j.1365-2222.1998.00239.x

Cited by 17 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The epithelium participates in eosinophil recruitment through production of adhesion molecules and chemokines [38]. In human allergic rhinitis, an increase in epithelial expression of ICAM-1 has been observed during natural allergen exposure [8] and after experimental allergen challenge [37]. There is little information on ICAM-1 expression in the mouse upper airway, but Asakura et al found that topically applied monoclonal anti-ICAM-1 antibody caused a significant attenuation of the eosinophil infiltration into nasal mucosa 24 h after nasal challenge with OVA in sensitized rats [9].…”

Section: Discussionmentioning

confidence: 99%

Induction, distribution and modulation of upper airway allergic inflammation in mice

Hussaın

Randolph

Brody

et al. 2001

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Induction, distribution and modulation of upper airway allergic inflammation in mice

Hussaın

Randolph

Brody

et al. 2001

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…The impact of INS on inflammatory mediators and cells that are the basis for nasal priming and hyperresponsiveness has been well described. In clinical trials of subjects with AR, INS inhibited allergen‐induced expression of ICAM‐1 on nasal epithelial cells [100,105]. Nasal airway infiltration, activation and survival of inflammatory cells such as eosinophils, basophils and mast cells were also reduced with INS treatment [104,106–110].…”

Section: Intranasal Corticosteroidsmentioning

confidence: 98%

Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies

Canonica

Compalati

2009

Clinical and Experimental Immunology

108

View full text Add to dashboard Cite

SummaryPatients with allergic rhinitis have traditionally been placed into 'seasonal' and 'perennial' categories, which do not account for the subclinical inflammatory state that exists in many patients. In subjects with seasonal and perennial allergic rhinitis, even subthreshold doses of allergen have been found to cause inflammatory cell infiltration in the nasal mucosa, including increases in expression of cellular adhesion molecules, nasal and conjunctival eosinophilia, and other markers of inflammation, which do not result in overt allergy symptoms. This state -which has been termed 'minimal persistent inflammation' -may contribute to hyperreactivity and increased susceptibility to development of clinical symptoms as well as common co-morbidities of allergic rhinitis, such as asthma. Treating overt allergy symptoms as well as this underlying inflammatory state requires agents that have well-established clinical efficacy, convenient administration, potent anti-inflammatory effects and proven long-term safety, so that long-term continuous administration is feasible. Of the three major classes of commonly used allergic rhinitis medications -intranasal corticosteroids, anti-histamines, and anti-leukotrienesintranasal corticosteroids appear to represent the most reasonable therapeutic option in patients who would benefit from continuous inhibition of persistent inflammation.

show abstract

“…Therefore, decreasing expression of sICAM-1 in epithelial cells is likely to be a therapeutic target in controlling AR. For example, topical steroid has been reported by Ciprandi et al [6] to reduce sICAM-1 expression in nasal epithelial cells in patients with AR. In the present study, we examine the expression of sICAM-1 in children with AR after nasal saline irrigation and evaluate the steroid nasal spray in controlling AR.…”

Section: Introductionmentioning

confidence: 99%

Nasal Saline Irrigation Facilitates Control of Allergic Rhinitis by Topical Steroid in Children

Sha

Zuo

et al. 2008

ORL

View full text Add to dashboard Cite

Objective: This study was designed to determine whether nasal saline irrigation improved the symptoms and signs of allergic rhinitis (AR) and whether nasal saline irrigation could be used as a complementary management of AR in children while less steroids were used. Method: 26 children with AR were divided into three groups and were given nasal saline irrigation and/or topical steroid. Symptoms and signs of AR and mucociliary clearance (MCC) were evaluated, and concentration of soluble intercellular adhesion molecule (sICAM)-1 in nasal secretion was detected. Results: In AR children treated with nasal irrigation and tapered topical steroid at week 8 and week 12, a significant improvement in symptoms and signs was observed, and a significant decrease in the mean values of MCC and the mean concentrations of sICAM-1 in nasal secretions was also detected. Conclusion: Nasal saline irrigation can be viewed as a good adjunctive treatment option for AR. It permitted the use of less topical steroids for controlling AR in children, which will contribute to fewer side effects and less economic burden.

show abstract

Intranasal fluticasone propionate reduces ICAM‐1 on nasal epithelial cells both during early and late phase after allergen challenge

Cited by 17 publications

References 23 publications

Induction, distribution and modulation of upper airway allergic inflammation in mice

Induction, distribution and modulation of upper airway allergic inflammation in mice

Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies

Nasal Saline Irrigation Facilitates Control of Allergic Rhinitis by Topical Steroid in Children

Contact Info

Product

Resources

About